Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Determining the metastatic viability of suspicious retroperitoneal nodes in testicular cancer with conventional imaging is challenging. The aim of this report is to review recent evidence in the utilization of novel imaging modalities to assess viable testicular cancer nodal metastases. Recent Evidence: Testicular germ cell tumors (TCGTs) follow a predictable lymphatic metastatic spread to the retroperitoneum. Accordingly, retroperitoneal imaging is critical in staging, assessing treatment response, and evaluating for recurrence. Conventional computed tomography (CT) imaging is effective in diagnosing pathologically enlarged lymph nodes but lacks the molecular information to determine if suspicious nodes harbor viable tumor. Positron emission tomography (PET) with the metabolic radiotracer 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG or FDG) has been shown to be useful in determining the presence of or absence of viable tumor after chemotherapy for seminoma, but its role with non-seminomatous germ cell tumors (NSGCTs) and other clinical scenarios is limited. Patients with residual masses after chemotherapy for NSGCT present a difficult challenge because surgical resection carries a high degree of morbidity despite many patients only harboring fibrosis on final pathology. Current imaging modalities are unable to effectively differentiate fibrosis from viable tumor on preoperative imaging. Novel molecular imaging techniques present promising opportunities to improve diagnosis in these patients. Summary: Novel imaging platforms have potential to improve the ability to determine viable nodal metastases regardless of size and structure but confirmatory studies are currently lacking.

Original languageEnglish (US)
Article number110
JournalCurrent Urology Reports
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Molecular Imaging
Testicular Neoplasms
Neoplasm Metastasis
Fibrosis
Drug Therapy
Neoplasms
Seminoma
Fluorodeoxyglucose F18
Positron-Emission Tomography
Lymph Nodes
Tomography
Pathology
Morbidity
Glucose
Recurrence
Nonseminomatous germ cell tumor
Therapeutics

Keywords

  • Germ cell tumors
  • Molecular imaging
  • Testis cancer

ASJC Scopus subject areas

  • Urology

Cite this

Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases. / Joice, Gregory A.; Rowe, Steven; Gorin, Michael; Pierorazio, Phillip Martin.

In: Current Urology Reports, Vol. 19, No. 12, 110, 01.12.2018.

Research output: Contribution to journalReview article

@article{4730422c7d8f489cb30d4a5a371da3dd,
title = "Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases",
abstract = "Purpose of Review: Determining the metastatic viability of suspicious retroperitoneal nodes in testicular cancer with conventional imaging is challenging. The aim of this report is to review recent evidence in the utilization of novel imaging modalities to assess viable testicular cancer nodal metastases. Recent Evidence: Testicular germ cell tumors (TCGTs) follow a predictable lymphatic metastatic spread to the retroperitoneum. Accordingly, retroperitoneal imaging is critical in staging, assessing treatment response, and evaluating for recurrence. Conventional computed tomography (CT) imaging is effective in diagnosing pathologically enlarged lymph nodes but lacks the molecular information to determine if suspicious nodes harbor viable tumor. Positron emission tomography (PET) with the metabolic radiotracer 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG or FDG) has been shown to be useful in determining the presence of or absence of viable tumor after chemotherapy for seminoma, but its role with non-seminomatous germ cell tumors (NSGCTs) and other clinical scenarios is limited. Patients with residual masses after chemotherapy for NSGCT present a difficult challenge because surgical resection carries a high degree of morbidity despite many patients only harboring fibrosis on final pathology. Current imaging modalities are unable to effectively differentiate fibrosis from viable tumor on preoperative imaging. Novel molecular imaging techniques present promising opportunities to improve diagnosis in these patients. Summary: Novel imaging platforms have potential to improve the ability to determine viable nodal metastases regardless of size and structure but confirmatory studies are currently lacking.",
keywords = "Germ cell tumors, Molecular imaging, Testis cancer",
author = "Joice, {Gregory A.} and Steven Rowe and Michael Gorin and Pierorazio, {Phillip Martin}",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s11934-018-0863-3",
language = "English (US)",
volume = "19",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "12",

}

TY - JOUR

T1 - Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases

AU - Joice, Gregory A.

AU - Rowe, Steven

AU - Gorin, Michael

AU - Pierorazio, Phillip Martin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose of Review: Determining the metastatic viability of suspicious retroperitoneal nodes in testicular cancer with conventional imaging is challenging. The aim of this report is to review recent evidence in the utilization of novel imaging modalities to assess viable testicular cancer nodal metastases. Recent Evidence: Testicular germ cell tumors (TCGTs) follow a predictable lymphatic metastatic spread to the retroperitoneum. Accordingly, retroperitoneal imaging is critical in staging, assessing treatment response, and evaluating for recurrence. Conventional computed tomography (CT) imaging is effective in diagnosing pathologically enlarged lymph nodes but lacks the molecular information to determine if suspicious nodes harbor viable tumor. Positron emission tomography (PET) with the metabolic radiotracer 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG or FDG) has been shown to be useful in determining the presence of or absence of viable tumor after chemotherapy for seminoma, but its role with non-seminomatous germ cell tumors (NSGCTs) and other clinical scenarios is limited. Patients with residual masses after chemotherapy for NSGCT present a difficult challenge because surgical resection carries a high degree of morbidity despite many patients only harboring fibrosis on final pathology. Current imaging modalities are unable to effectively differentiate fibrosis from viable tumor on preoperative imaging. Novel molecular imaging techniques present promising opportunities to improve diagnosis in these patients. Summary: Novel imaging platforms have potential to improve the ability to determine viable nodal metastases regardless of size and structure but confirmatory studies are currently lacking.

AB - Purpose of Review: Determining the metastatic viability of suspicious retroperitoneal nodes in testicular cancer with conventional imaging is challenging. The aim of this report is to review recent evidence in the utilization of novel imaging modalities to assess viable testicular cancer nodal metastases. Recent Evidence: Testicular germ cell tumors (TCGTs) follow a predictable lymphatic metastatic spread to the retroperitoneum. Accordingly, retroperitoneal imaging is critical in staging, assessing treatment response, and evaluating for recurrence. Conventional computed tomography (CT) imaging is effective in diagnosing pathologically enlarged lymph nodes but lacks the molecular information to determine if suspicious nodes harbor viable tumor. Positron emission tomography (PET) with the metabolic radiotracer 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG or FDG) has been shown to be useful in determining the presence of or absence of viable tumor after chemotherapy for seminoma, but its role with non-seminomatous germ cell tumors (NSGCTs) and other clinical scenarios is limited. Patients with residual masses after chemotherapy for NSGCT present a difficult challenge because surgical resection carries a high degree of morbidity despite many patients only harboring fibrosis on final pathology. Current imaging modalities are unable to effectively differentiate fibrosis from viable tumor on preoperative imaging. Novel molecular imaging techniques present promising opportunities to improve diagnosis in these patients. Summary: Novel imaging platforms have potential to improve the ability to determine viable nodal metastases regardless of size and structure but confirmatory studies are currently lacking.

KW - Germ cell tumors

KW - Molecular imaging

KW - Testis cancer

UR - http://www.scopus.com/inward/record.url?scp=85056267336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056267336&partnerID=8YFLogxK

U2 - 10.1007/s11934-018-0863-3

DO - 10.1007/s11934-018-0863-3

M3 - Review article

VL - 19

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 12

M1 - 110

ER -